Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Cipriani, Sara ^a   Desjardins, Cody A ^a   Burdett, Thomas C ^a   Xu, Yuehang ^a   Xu, Kui ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; URATE; URATE OXIDASE; RECOMBINANT PROTEIN; URIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN ATROPHY; CELL DEGENERATION; CELL LEVEL; CELL LOSS; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENRICHMENT CULTURE; GENE OVEREXPRESSION; GLIA CELL; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; TRANSGENE; UOX GENE; ANIMAL; C57BL MOUSE; DRUG EFFECT; GENETICS; METABOLISM; NERVE DEGENERATION; PARKINSONISM; PATHOLOGY; TISSUE CULTURE TECHNIQUE; TRANSGENIC MOUSE;

MUS;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ASTROCYTES; DOPAMINERGIC NEURONS; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE DEGENERATION; PARKINSONIAN DISORDERS; RECOMBINANT PROTEINS; TISSUE CULTURE TECHNIQUES; URATE OXIDASE; URIC ACID;

EID: 84861006456     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037331     Document Type: Article

References (56)

1. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, et al. (1994) Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 91 (2): 742-746.
2. Truszkowski R, Goldmanowna C, (1933) Uricase and its action: Distribution in various animals. Biochem J 27 (3): 612-614.
3. Yeldandi AV, Yeldandi V, Kumar S, Murthy CV, Wang XD, et al. (1991) Molecular evolution of the urate oxidase-encoding gene in hominoid primates: Nonsense mutations. Gene 109 (2): 281-284.
4. Wu XW, Muzny DM, Lee CC, Caskey CT, (1992) Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34 (1): 78-84.
5. Oda M, Satta Y, Takenaka O, Takahata N, (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19 (5): 640-653.
6. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 (6887): 447-452.
7. Ames BN, Cathcart R, Schwiers E, Hochstein P, (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci U S A 78 (11): 6858-6862.
8. Green CJ, Healing G, Simpkin S, Fuller BJ, Lunec J, (1986) Reduced susceptibility to lipid peroxidation in cold ischemic rabbit kidneys after addition of desferrioxamine, mannitol, or uric acid to the flush solution. Cryobiology 23 (4): 358-365.
9. Arduini A, Mancinelli G, Radatti GL, Hochstein P, Cadenas E, (1992) Possible mechanism of inhibition of nitrite-induced oxidation of oxyhemoglobin by ergothioneine and uric acid. Arch Biochem Biophys 294 (2): 398-402.
10. Haldane JB, (1955) Origin of man. Nature 176 (4473): 169-170.
11. Orowan E, (1955) The origin of man. Nature 175 (4459): 683-684.
12. Wu XW, Lee CC, Muzny DM, Caskey CT, (1989) Urate oxidase: Primary structure and evolutionary implications. Proc Natl Acad Sci U S A 86 (23): 9412-9416.
13. Proctor P, (1970) Similar functions of uric acid and ascorbate in man? Nature 228 (5274): 868.
14. Whiteman M, Ketsawatsakul U, Halliwell B, (2002) A reassessment of the peroxynitrite scavenging activity of uric acid. Ann N Y Acad Sci 962: 242-259.
15. Davies KJ, Sevanian A, Muakkassah-Kelly SF, Hochstein P, (1986) Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. Biochem J 235 (3): 747-754.
16. Church WH, Ward VL, (1994) Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation. Brain Res Bull 33 (4): 419-425.
17. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A, (2007) Plasma urate and risk of parkinson's disease. Am J Epidemiol 166 (5): 561-567.
18. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM, (2005) Serum uric acid levels and the risk of parkinson disease. Ann Neurol 58 (5): 797-800.
19. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, et al. (1996) Observations on serum uric acid levels and the risk of idiopathic parkinson's disease. Am J Epidemiol 144 (5): 480-484.
20. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, et al. (2008) Serum urate as a predictor of clinical and radiographic progression in parkinson disease. Arch Neurol 65 (6): 716-723.
21. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, et al. (2009) Urate as a predictor of the rate of clinical decline in parkinson disease. Arch Neurol 66 (12): 1460-1468.
22. Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, et al. (2011) Serum urate and probability of dopaminergic deficit in early "parkinson's disease". Mov Disord 26 (10): 1864-1868.
23. Andreadou E, Nikolaou C, Gournaras F, Rentzos M, Boufidou F, et al. (2009) Serum uric acid levels in patients with parkinson's disease: Their relationship to treatment and disease duration. Clin Neurol Neurosurg 111 (9): 724-728.
24. Stinefelt B, Leonard SS, Blemings KP, Shi X, Klandorf H, (2005) Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid. Ann Clin Lab Sci 35 (1): 37-45.
25. Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, et al. (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: Potentiation by low-level depolarization. J Neurochem 109 (4): 1118-1128.
26. Zhu TG, Wang XX, Luo WF, Zhang QL, Huang TT, et al. (2011) Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci Lett 506 (2): 175-9.
27. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, et al. (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of parkinson's disease. J Neurochem 80 (1): 101-110.
28. Haberman F, Tang SC, Arumugam TV, Hyun DH, Yu QS, et al. (2007) Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med 9 (4): 315-323.
29. Wang LJ, Luo WF, Wang HH, Ni GH, Ye Y, et al. (2010) Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats. Zhonghua Yi Xue Za Zhi 90 (19): 1362-1365.
30. Vila M, Przedborski S, (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4 (5): 365-375.
31. Langston JW, Ballard P, Tetrud JW, Irwin I, (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (4587): 979-980.
32. Mayer RA, Kindt MV, Heikkila RE, (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47 (4): 1073-1079.
33. Cleeter MW, Cooper JM, Schapira AH, (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J Neurochem 58 (2): 786-789.
34. Mizuno Y, Suzuki K, Sone N, Saitoh T, (1987) Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains. Neurosci Lett 81 (1-2): 204-208.
35. Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL, (2007) Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 55 (5): 463-472.
36. Wang T, Pei Z, Zhang W, Liu B, Langenbach R, et al. (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19 (9): 1134-1136.
37. Kono H, Chen CJ, Ontiveros F, Rock KL, (2010) Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 120 (6): 1939-1949.
38. Schmidt AP, Bohmer AE, Antunes C, Schallenberger C, Porciuncula LO, et al. (2009) Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: Role of A1 adenosine receptors. Br J Pharmacol 156 (1): 163-172.
39. Scott GS, Cuzzocrea S, Genovese T, Koprowski H, Hooper DC, (2005) Uric acid protects against secondary damage after spinal cord injury. Proc Natl Acad Sci U S A 102 (9): 3483-3488.
40. Aoyama K, Matsumura N, Watabe M, Wang F, Kikuchi-Utsumi K, et al. (2011) Caffeine and uric acid mediate glutathione synthesis for neuroprotection. Neuroscience 181: 206-215.
41. Gomez FJ, Aguirre P, Gonzalez-Billault C, Nunez MT, (2011) Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+). J Neural Transm 118 (3): 421-431.
42. Park TH, Kwon OS, Park SY, Han ES, Lee CS, (2003) N-methylated beta-carbolines protect PC12 cells from cytotoxic effect of MPP+ by attenuation of mitochondrial membrane permeability change. Neurosci Res 46 (3): 349-358.
43. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, et al. (2003) 1-methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: Role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 371(Pt 1): 151-164.
44. Lee CS, Han JH, Jang YY, Song JH, Han ES, (2002) Differential effect of catecholamines and MPP(+) on membrane permeability in brain mitochondria and cell viability in PC12 cells. Neurochem Int 40 (4): 361-369.
45. Thorn NA, Nielsen FS, Jeppesen CK, (1991) Characteristics of ascorbic acid uptake by isolated ox neurohypophyseal nerve terminals and the influence of glucocorticoid and tri-iodothyronine on uptake. Acta Physiol Scand 141 (1): 97-106.
46. May JM, Li L, Hayslett K, Qu ZC, (2006) Ascorbate transport and recycling by SH-SY5Y neuroblastoma cells: Response to glutamate toxicity. Neurochem Res 31 (6): 785-794.
47. Huang J, May JM, (2006) Ascorbic acid protects SH-SY5Y neuroblastoma cells from apoptosis and death induced by beta-amyloid. Brain Res 1097 (1): 52-58.
48. Gess B, Sevimli S, Strecker JK, Young P, Schabitz WR, (2011) Sodium-dependent vitamin C transporter 2 (SVCT2) expression and activity in brain capillary endothelial cells after transient ischemia in mice. PLoS One 6 (2): e17139.
49. Scheers NM, Sandberg AS, (2011) Iron regulates the uptake of ascorbic acid and the expression of sodium-dependent vitamin C transporter 1 (SVCT1) in human intestinal caco-2 cells. Br J Nutr 1-7.
50. Chen PS, Peng GS, Li G, Yang S, Wu X, et al. (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 11 (12): 1116-1125.
51. Wong SS, Li RH, Stadlin A, (1999) Oxidative stress induced by MPTP and MPP(+): Selective vulnerability of cultured mouse astrocytes. Brain Res 836 (1-2): 237-244.
52. Wu EY, Langston JW, Di Monte DA, (1992) Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes. J Pharmacol Exp Ther 262 (1): 225-230.
53. Volterra A, Trotti D, Floridi S, Racagni G, (1994) Reactive oxygen species inhibit high-affinity glutamate uptake: Molecular mechanism and neuropathological implications. Ann N Y Acad Sci 738: 153-162.
54. Hazell AS, Itzhak Y, Liu H, Norenberg MD, (1997) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 68 (5): 2216-2219.
55. Uezono T, Matsubara K, Shimizu K, Mizukami H, Ogawa K, et al. (2001) Glutamate is not involved in the MPP+-induced dopamine overflow in the striatum of freely moving C57BL/6 mice. J Neural Transm 108 (8-9): 899-908.
56. Michel PP, Agid Y, (1992) The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures. Brain Res 597 (2): 233-240.